The Swedish company Xvivo Perfusion has made a recommended public offer to holders of shares in Vivoline Medical.
The company offers for every share in Vivoline 1.2921 Swedish crown in cash and 0.1543 shares in Xvivo Perfusion. The consideration corresponds to a value of about 9.32 Swedish crowns per share. The company says the total value of the offer amounts to about 128.5 million Swedish crowns ($15.79 million). The cash part of the offer is fully funded by Xvivo Perfusion’s own current liquid funds.